Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Funcategorized%2Fdiscontinuation-of-omalizumab-during-covid-19-pandemic-associated-with-poor-outcomes-for-chronic-spontaneous-urticaria%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=34.225.194.102&categories=Uncategorized): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
Discontinuation of omalizumab during COVID-19 pandemic associated with poor outcomes for chronic spontaneous urticaria - Medical Conferences

Home > Discontinuation of omalizumab during COVID-19 pandemic associated with poor outcomes for chronic spontaneous urticaria

Discontinuation of omalizumab during COVID-19 pandemic associated with poor outcomes for chronic spontaneous urticaria

Presented By
Dr Ailye Sevdem Gulcan, Bezmialem Vakif University, Turkey

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
EADV 2020
Urticaria activity scores (UAS) went up and urticaria control test (UCT) scores went down in patients with chronic spontaneous urticaria who discontinued omalizumab during the COVID-19 pandemic.

Dr Ailye Sevdem Gulcan’s (Bezmialem Vakif University, Turkey) poster presented the results of a single-centre, cross-sectional study that followed 43 patients with a diagnosis of chronic spontaneous urticaria  [1]. On account of the COVID-19 pandemic, 15 of the patients (34.9%) discontinued their omalizumab injections. All 43 patients were interviewed by phone and completed the UAS and UCT questionnaires; these results were then compared with previous UAS and UCT scores in their files.

In patients who had discontinued omalizumab, there was a statistically significant increase in their UAS scores and a statistically significant decrease in their UCT scores. Among the patients who had kept up their omalizumab treatment regimen, neither their UAS nor their UCT scores were significantly different.

The team concludes that the COVID-19 pandemic has had a negative impact on the management of CSU in patients who discontinued their treatment protocol due to the pandemic.

 


    1. Gulcan S. Impact of COVID-19 Pandemic on Chronic Spontaneous urticaria: A Cross-sectional study from Turkey. P1616, EADV Virtual Congres, 29-31 October 2020.

 



Posted on